This research illustrated the mechanism of ANRIL and miR-181a in the occurrence and development of pancreatic carcinoma, which might provide a novel strategy for pancreatic carcinoma therapy. This evidence concerns the gene CDKN2B-AS1 and exocrine pancreatic carcinoma.